JP7297685B2 - 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 - Google Patents

唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 Download PDF

Info

Publication number
JP7297685B2
JP7297685B2 JP2019570491A JP2019570491A JP7297685B2 JP 7297685 B2 JP7297685 B2 JP 7297685B2 JP 2019570491 A JP2019570491 A JP 2019570491A JP 2019570491 A JP2019570491 A JP 2019570491A JP 7297685 B2 JP7297685 B2 JP 7297685B2
Authority
JP
Japan
Prior art keywords
dosage form
saliva
composition
acid
melatonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524162A5 (cg-RX-API-DMAC7.html
JP2020524162A (ja
Inventor
エム. シャー,サイド
ハッサン,ダニエル
ハッサン,フレッド
コルジノ,パトリック
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2020524162A publication Critical patent/JP2020524162A/ja
Publication of JP2020524162A5 publication Critical patent/JP2020524162A5/ja
Application granted granted Critical
Publication of JP7297685B2 publication Critical patent/JP7297685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019570491A 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 Active JP7297685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
US62/522,473 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (3)

Publication Number Publication Date
JP2020524162A JP2020524162A (ja) 2020-08-13
JP2020524162A5 JP2020524162A5 (cg-RX-API-DMAC7.html) 2022-08-03
JP7297685B2 true JP7297685B2 (ja) 2023-06-26

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570491A Active JP7297685B2 (ja) 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200018652A (cg-RX-API-DMAC7.html)
CN (1) CN110913853A (cg-RX-API-DMAC7.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC7.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC7.html)
CA (1) CA3067822C (cg-RX-API-DMAC7.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019015733A (cg-RX-API-DMAC7.html)
RU (1) RU2020101742A (cg-RX-API-DMAC7.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC7.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120195968A1 (en) 2011-01-28 2012-08-02 Shah Syed M Controlled-release melatonin compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
US20140303227A1 (en) 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
JP2014237700A (ja) 2007-04-11 2014-12-18 ファーマシューティカル プロダクションズ, インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
WO2016141069A1 (en) 2015-03-02 2016-09-09 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014237700A (ja) 2007-04-11 2014-12-18 ファーマシューティカル プロダクションズ, インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
US20120195968A1 (en) 2011-01-28 2012-08-02 Shah Syed M Controlled-release melatonin compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
US20140303227A1 (en) 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
WO2016141069A1 (en) 2015-03-02 2016-09-09 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
:H. Munoz et al., International Journal of Pharmaceutics (2014) 467 84-89,

Also Published As

Publication number Publication date
WO2018236678A1 (en) 2018-12-27
US20200268886A1 (en) 2020-08-27
KR20200018652A (ko) 2020-02-19
US11224658B2 (en) 2022-01-18
RU2020101742A (ru) 2021-07-20
AU2018289284A1 (en) 2020-01-16
US20180360967A1 (en) 2018-12-20
SG11201912172YA (en) 2020-01-30
US10960075B2 (en) 2021-03-30
US11224657B2 (en) 2022-01-18
CN110913853A (zh) 2020-03-24
US20200069803A1 (en) 2020-03-05
US20200268887A1 (en) 2020-08-27
BR122021012549B1 (pt) 2022-02-22
ES2979335T3 (es) 2024-09-25
BR122021012549B8 (pt) 2022-10-25
CA3067822A1 (en) 2018-12-27
BR112019027286A2 (pt) 2020-07-21
EP3641759B1 (en) 2024-04-03
BR112019027286B1 (pt) 2022-02-22
US10500280B2 (en) 2019-12-10
EP3641759A4 (en) 2021-03-24
JP2020524162A (ja) 2020-08-13
CA3067822C (en) 2022-08-30
MX2019015733A (es) 2020-02-20
EP3641759A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
US11224657B2 (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Dixit et al. Oral strip technology: Overview and future potential
DK2701681T3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANESTHETICS as bupivacaine for local administration to the mouth or throat
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
Chauhan et al. A comprehensive review on mucoadhesive drug delivery
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
JP5284070B2 (ja) 口腔内粘膜貼付製剤
CN110650732A (zh) 锭剂剂型
US20180318228A1 (en) Method for a slow release of drugs from orally dissolving capsules
WO2022157563A1 (en) A pharmaceutical composition comprising lidocaine and melatonin
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
HK40019696A (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Singh et al. A review on mouth dissolving film-a novel approach
Repka et al. Matrix-and reservoir-based transmucosal delivery systems: tailoring delivery solutions
HK40110942A (en) Transmucosal therapeutic system containing agomelatine
JP2011201817A (ja) 口腔貼付用錠剤
CN107296798A (zh) 抗发红组合物
TW201801717A (zh) 包含局部麻醉劑之快速崩解口腔薄膜

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210609

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230614

R150 Certificate of patent or registration of utility model

Ref document number: 7297685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250